CUSIP G52694109ORD SHS CL AQ4 2025
Aggregate 13F value by quarter
Multi-quarter trend — upgrade to see history
UpgradeQ4 2025
221 funds hold this security · Q4 2025
| # | Fund | Shares | Value | Δ Shares | Activity |
|---|---|---|---|---|---|
| 1 | Rubric Capital Management LP | 3.33M | $137.31M | −671.3K | Reduced |
| 2 | Vanguard Group Inc | 3.11M | $128.41M | +49.8K | Added |
| 3 | Baker Bros. Advisors LP | 2.83M | $116.58M | +1.6K | Added |
| 4 | Tang Capital Management LLC | 2.26M | $93.22M |
| −68.7K |
| Reduced |
| 5 | Fmr LLC | 1.64M | $67.77M | +843.1K | Added |
| 6 | Morgan Stanley | 1.36M | $56.10M | −2.9K | Reduced |
| 7 | Fairmount Funds Management LLC | 1.32M | $54.44M | −453.2K | Reduced |
| 8 | D. E. Shaw & Co., Inc. | 1.24M | $51.22M | +107.4K | Added |
| 9 | Arrowstreet Capital, Limited Partnership | 1.07M | $44.06M | −47 | Reduced |
| 10 | Bnp Paribas Financial Markets | 831.8K | $34.31M | +178.4K | Added |
See every fund holding Kiniksa Pharmaceuticals Intl, with full quarter-over-quarter share changes.
Unlock all holders